Korg

Israel based medical technology company HIL Applied Medical has acquired laser-based cancer therapy components developer, Nanolabz, a part of the University of Nevada, to assist in developing new cancer proton therapy systems.

University of Nevada enterprise and innovation associate vice-president Dr Ellen Purpus, who had assisted in drafting the license agreement stated that the acquisition will help in validating the research, innovation and commercialisation at the University.

HIL CEO Sagi Brink-Danan said: "Today’s announcement is an important step towards the developing of our advanced cancer therapy systems.

"Today’s announcement is an important step towards the developing of our advanced cancer therapy systems."

"Still this is only one step in a long process, and we look forward to expanding the collaboration with the University of Nevada, Reno and the Nanolabz team."

The proton therapy involves the exposiing of cancerous tumours to a form of focused radiation, two to six times less damage is caused to the surrounding healthy tissues subsequently reducing toxicity.

It is an advanced radiation form of the conventional radiation therapies and improves the quality of the patient’s life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cleared by the US Food and Drug Administration (FDA) and covered by both federal and private insurers, the proton therapy is administered to treat a range of cancers on a regular basis.

However, a rapid adoption of the proton therapy is hindered by the lack of appropriate infrastructure in hospital facilities. The therapy requires a huge space as large as that of a football field entailing high-costs.

Vendors are being introduced to a single-room solution at a lower cost.


Image: Nanolabz co-founder and president Grant Korgan. Photo: courtesy of PR Newswire Association LLC.